What Does Gilead Sciences (GILD) Gain From Its New Solid Tumor Partnership?

Gilead Sciences (NasdaqGS:GILD) announced a collaboration with Vir Biotechnology to develop novel T cell engagers for solid tumors. The agreement grants Gilead exclusive rights to further develop and commercialize T cell engager candidates using Vir's technology platform. Vir's expertise in immunology and antibody engineering will be applied to create targeted therapies aimed at patients with solid tumor cancers. The new Gilead and Vir T cell engager collaboration for solid tumors is an...